Cellulite afflicts 80% of post-pubertal females of all races; men are rarely affected. To diminish or eliminate this condition, patients spend billions of dollars annually on treatments that are largely ineffective.
SkinCare Research, near Boston, along with SkinCare Physicians’ Drs. Michael Kaminer and Deanne Robinson, recently completed over 3 years of clinical trials on a new cellulite treatment device that has been shown to be safe and effective in reducing the appearance of cellulite. Cellulite is a term used to describe the dimpled appearance of skin caused by subcutaneous fat deposits and fibrous septae. The new device, developed by Cabochon Aesthetics, is intended to provide a controlled subcutaneous release of the fibrous septae that contribute to cellulite.
Our research center enrolled over 60 subjects into controlled trials. Subjects were seen at intervals of 1, 2, and 3 months with extended follow-ups at 1 and 3 years. Subject satisfaction was high, recovery time minimal and most subjects reported they would recommend the procedure to friends. After thorough analysis of the results the data was submitted to the FDA and approval was granted at the end of the summer 2013.
We are proud to have been an integral part of gaining approval for this new cellulite treatment and we hope to offer this therapy option in the near future to our SkinCare Physicians’ patients. For more information contact us online or call (617) 848-1638.